Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL vs DHA-PPQ for Malaria in Malawian Children
NCT01038063Phase 4Unknown
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Oct 2010
- Primary completion
- Sep 2013
- Modality
- Bivalent/Multivalent Binders, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine and dihydroartemisinin + piperaquine in malaria, sponsored by Liverpool School of Tropical Medicine. Primary endpoint: Prevalence of ototoxicity at 36 months. Status: unknown.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01038063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01038063.